18.07.2017 23:02:17
|
Vertex Reports Positive Data From Combination Regimens To Treat Cystic Fibrosis
(RTTNews) - Vertex Pharmaceuticals Inc. (VRTX) announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis who have one F508del mutation and one minimal function mutation. The company said the triple combination regimens were generally well tolerated across all three studies, and the majority of adverse events were mild to moderate in severity. Across the studies, the discontinuation rate due to adverse events was low.
Jeffrey Chodakewitz, Chief Medical Officer at Vertex, stated: "We will be collecting and evaluating additional data from these and other studies and will make a decision on which regimen(s) to take forward into pivotal program(s), which we expect to begin in the first half of 2018."
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Vertex Pharmaceuticals Inc.mehr Nachrichten
31.01.25 |
Schwacher Handel in New York: NASDAQ Composite schließt in der Verlustzone (finanzen.at) | |
31.01.25 |
Börse New York in Rot: S&P 500 notiert letztendlich im Minus (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: NASDAQ Composite-Börsianer greifen am Freitagnachmittag zu (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 verbucht am Freitagnachmittag Gewinne (finanzen.at) | |
31.01.25 |
Pluszeichen in New York: Pluszeichen im NASDAQ 100 (finanzen.at) | |
31.01.25 |
NASDAQ Composite-Handel aktuell: NASDAQ Composite-Anleger greifen zu (finanzen.at) | |
31.01.25 |
NASDAQ 100-Handel aktuell: NASDAQ 100 legt am Mittag zu (finanzen.at) | |
31.01.25 |
Börse New York in Grün: S&P 500 mit positivem Vorzeichen (finanzen.at) |
Analysen zu Vertex Pharmaceuticals Inc.mehr Analysen
Aktien in diesem Artikel
Vertex Pharmaceuticals Inc. | 444,40 | 5,26% |